BioCentury | Aug 13, 2020
Product Development

GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

...it’s the same cost there.”SAB’s transgenic cowsLike GigaGen, SAB Biotherapeutics Inc....
...the two Phase I studies of SAB-185. Sandi Wong SAB-185 SAB Biotherapeutics Inc. GigaGen...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...90% percent of trading in the company’s securities takes place on NASDAQ. Cash for COVID SAB Biotherapeutics Inc....
BioCentury | Apr 24, 2020
Product Development

Behind SAB’s rapid response to COVID-19

...is more consistent and easier to scale up than convalescent plasma from recovered COVID-19 patients. SAB Biotherapeutics Inc....
...review. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor SAB Biotherapeutics Inc. SAB-185 COVID-19 cov19count SARS-CoV-2 cov19count...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

...to order and administer COVID-19 tests that have been authorized by FDA. Trio of deals SAb Biotherapeutics Inc....
...Wong, Assistant Editor and Elizabeth S. Eaton, Staff Writer I-Mab Biopharma U.S. Department of Health and Human Services SAB Biotherapeutics Inc. CSL...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...hyperimmune therapy by purifying and concentrating plasma from individuals who have recovered from SARS-CoV-2 infection. SAb Biotherapeutics Inc....
...Editor CAP-1002 Mayo Clinic U.S. Food and Drug Administration (FDA) U.S. Department of Health and Human Services GlaxoSmithKline plc Emergent BioSolutions Inc. SAB Biotherapeutics Inc. Biotechnology...
BioCentury | May 2, 2019
Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

...well for activation of the entire immune system,” Eddie Sullivan, co-founder, president and CEO of SAB Biotherapeutics Inc....
...horse antibodies. SAB owns DiversitAb, which was conceived at the University of Massachusetts. COMPANY PROFILE SAB Biotherapeutics Inc....
...Inc. (NASDAQ:REGN), Tarrytown, N.Y. SAB Biotherapeutics Inc., Sioux Falls, S.D. University of Massachusetts, Amherst, Mass. Sandi Wong, Staff Writer SAB Biotherapeutics Inc. Influenza...
BioCentury | Jan 4, 2019
Financial News

SAB Biotherapeutics raises $22M in series A-2 round

...Immunotherapy company SAB Biotherapeutics Inc. (Sioux Falls, S.D.) raised $22 million in a series A-2 round. T. Denny...
...$10 million to the round, which closed on Dec. 15. SAB Biotherapeutics Inc., Sioux Falls, S.D. Elizabeth S. Eaton SAB Biotherapeutics Inc....
BioCentury | Aug 31, 2018
Clinical News

SAB's SAB-139 protects non-human primates from Ebola virus infection

...DiversitAb platform. SAB Biotherapeutics Inc., Sioux Falls, S.D. Product: SAB-139 Business: Infectious Indication: Treat Ebola virus infection Sandi Wong SAB-139 SAB Biotherapeutics Inc....
BioCentury | Aug 22, 2016
Clinical News

SAB-301: Phase I started

...2.5, 5, 10, 20 and 50 mg/kg IV SAB-301 in about 70 healthy adult volunteers. SAB Biotherapeutics Inc....
BioCentury | Mar 31, 2016
Translation in Brief

Cattle call

...an artificial human chromosome. Last month, a team from the Naval Medical Research Center , SAB Biotherapeutics Inc....
Items per page:
1 - 10 of 11
BioCentury | Aug 13, 2020
Product Development

GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

...it’s the same cost there.”SAB’s transgenic cowsLike GigaGen, SAB Biotherapeutics Inc....
...the two Phase I studies of SAB-185. Sandi Wong SAB-185 SAB Biotherapeutics Inc. GigaGen...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...90% percent of trading in the company’s securities takes place on NASDAQ. Cash for COVID SAB Biotherapeutics Inc....
BioCentury | Apr 24, 2020
Product Development

Behind SAB’s rapid response to COVID-19

...is more consistent and easier to scale up than convalescent plasma from recovered COVID-19 patients. SAB Biotherapeutics Inc....
...review. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor SAB Biotherapeutics Inc. SAB-185 COVID-19 cov19count SARS-CoV-2 cov19count...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

...to order and administer COVID-19 tests that have been authorized by FDA. Trio of deals SAb Biotherapeutics Inc....
...Wong, Assistant Editor and Elizabeth S. Eaton, Staff Writer I-Mab Biopharma U.S. Department of Health and Human Services SAB Biotherapeutics Inc. CSL...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...hyperimmune therapy by purifying and concentrating plasma from individuals who have recovered from SARS-CoV-2 infection. SAb Biotherapeutics Inc....
...Editor CAP-1002 Mayo Clinic U.S. Food and Drug Administration (FDA) U.S. Department of Health and Human Services GlaxoSmithKline plc Emergent BioSolutions Inc. SAB Biotherapeutics Inc. Biotechnology...
BioCentury | May 2, 2019
Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

...well for activation of the entire immune system,” Eddie Sullivan, co-founder, president and CEO of SAB Biotherapeutics Inc....
...horse antibodies. SAB owns DiversitAb, which was conceived at the University of Massachusetts. COMPANY PROFILE SAB Biotherapeutics Inc....
...Inc. (NASDAQ:REGN), Tarrytown, N.Y. SAB Biotherapeutics Inc., Sioux Falls, S.D. University of Massachusetts, Amherst, Mass. Sandi Wong, Staff Writer SAB Biotherapeutics Inc. Influenza...
BioCentury | Jan 4, 2019
Financial News

SAB Biotherapeutics raises $22M in series A-2 round

...Immunotherapy company SAB Biotherapeutics Inc. (Sioux Falls, S.D.) raised $22 million in a series A-2 round. T. Denny...
...$10 million to the round, which closed on Dec. 15. SAB Biotherapeutics Inc., Sioux Falls, S.D. Elizabeth S. Eaton SAB Biotherapeutics Inc....
BioCentury | Aug 31, 2018
Clinical News

SAB's SAB-139 protects non-human primates from Ebola virus infection

...DiversitAb platform. SAB Biotherapeutics Inc., Sioux Falls, S.D. Product: SAB-139 Business: Infectious Indication: Treat Ebola virus infection Sandi Wong SAB-139 SAB Biotherapeutics Inc....
BioCentury | Aug 22, 2016
Clinical News

SAB-301: Phase I started

...2.5, 5, 10, 20 and 50 mg/kg IV SAB-301 in about 70 healthy adult volunteers. SAB Biotherapeutics Inc....
BioCentury | Mar 31, 2016
Translation in Brief

Cattle call

...an artificial human chromosome. Last month, a team from the Naval Medical Research Center , SAB Biotherapeutics Inc....
Items per page:
1 - 10 of 11